Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial

Paul Glasziou, Jan Alexander, Elaine Beller, Philip Clarke, John Chalmers, Stephen MacMahon, Mark Cooper, Eleuterio Ferrannini, Paul Glasziou, Diederick Grobbee, Pavel Hamet, Stephen Harrap, Simon Heller, Liu Lisheng, Giuseppe Mancia, Michel Marre, Carl Mogensen, Bruce Neal, Chang Yu Pan, Anushka Patel & 50 others Neil Poulter, Anthony Rodgers, Bryan William, Mark Woodward, Rory Collins, Rury Holman, Peter Sleight, Mark Adams, Michael Branley, Greg Fulcher, Bronwyn Jenkins, Damien Louis, Wei Lou, Harry Lowe, Anne McCormack, Paul Mitchell, Stephen Ong, Carol Pollock, John Watson, Tien Wong, Sarah Allen, Severine Bompoint, Anna Carreras, Tom Chen, Samatha Flynn, Sophie Gibbo, Dorothy Han, Sally Hough, Kathy Jayne, Roshina Joshi, Andrew Pascal Kengne, Jennifer Linn, Helen Monaghan, Robyn Ng, Vlado Perkovic, Joanne Regaglia, Manuela Schmidt, Du Xin, Bi Yufang, Terry Holloway, Barry Gray, Amanda Milne, Alison Adderkin, Marie Renee Guertin, Danielle de Guise, Ma Liyuan, Jane Reid, Ravathi Subramaniam, Wang Wen, Karin Williamson

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Background: Diabetes has a high burden of illness both in life years lost and in disability through related co-morbidities. Accurate assessment of the non-mortality burden requires appropriate health-related quality of life and summary utility measures of which there are several contenders. The study aimed to measure the impact of diabetes on various health-related quality of life domains, and compare several summary utility measures. Methods: In the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) study, 978 Australian patients with Type 2 diabetes completed two health-related quality of life questionnaires at baseline: the EQ-5D and the SF-36v2, from which nine summary utility measures were calculated, and compared. The algorithms were grouped into four classes: (i) based on the EQ-5D; (ii) using fewer items than those in the SF-12 (iii) using the items in the SF-12; and (iv) using all items of the SF-36. Results: Overall health-related quality of life of the subjects was good (mean utility ranged from 0.68 (±0.08) to 0.85(±0.14) over the nine utility measures) and comparable to patients without diabetes. Summary indices were well correlated with each other (r = 0.76 to 0.99), and showed lower health-related quality of life in patients with major diabetes-related events such as stroke or myocardial infarction. Despite the smaller number of items used in the scoring of the EQ-5D, it generally performed at least as well as SF-36 based methods. However, all utility measures had some limitation such as limited range or ceiling effects. Conclusion: The summary utility measures showed good agreement, and showed good discrimination between major and minor health state changes. However, EQ-5D based measures performed as well and are generally simpler to use.

Original languageEnglish
Article number21
JournalHealth and Quality of Life Outcomes
Volume5
DOIs
Publication statusPublished - Apr 27 2007

Fingerprint

Type 2 Diabetes Mellitus
Quality of Life
perindopril drug combination indapamide
Gliclazide
Cost of Illness
Vascular Diseases
Stroke
Myocardial Infarction
Morbidity
Health

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. / Glasziou, Paul; Alexander, Jan; Beller, Elaine; Clarke, Philip; Chalmers, John; MacMahon, Stephen; Cooper, Mark; Ferrannini, Eleuterio; Glasziou, Paul; Grobbee, Diederick; Hamet, Pavel; Harrap, Stephen; Heller, Simon; Lisheng, Liu; Mancia, Giuseppe; Marre, Michel; Mogensen, Carl; Neal, Bruce; Yu Pan, Chang; Patel, Anushka; Poulter, Neil; Rodgers, Anthony; William, Bryan; Woodward, Mark; Collins, Rory; Holman, Rury; Sleight, Peter; Adams, Mark; Branley, Michael; Fulcher, Greg; Jenkins, Bronwyn; Louis, Damien; Lou, Wei; Lowe, Harry; McCormack, Anne; Mitchell, Paul; Ong, Stephen; Pollock, Carol; Watson, John; Wong, Tien; Allen, Sarah; Bompoint, Severine; Carreras, Anna; Chen, Tom; Flynn, Samatha; Gibbo, Sophie; Han, Dorothy; Hough, Sally; Jayne, Kathy; Joshi, Roshina; Kengne, Andrew Pascal; Linn, Jennifer; Monaghan, Helen; Ng, Robyn; Perkovic, Vlado; Regaglia, Joanne; Schmidt, Manuela; Xin, Du; Yufang, Bi; Holloway, Terry; Gray, Barry; Milne, Amanda; Adderkin, Alison; Guertin, Marie Renee; de Guise, Danielle; Liyuan, Ma; Reid, Jane; Subramaniam, Ravathi; Wen, Wang; Williamson, Karin.

In: Health and Quality of Life Outcomes, Vol. 5, 21, 27.04.2007.

Research output: Contribution to journalArticle

Glasziou, P, Alexander, J, Beller, E, Clarke, P, Chalmers, J, MacMahon, S, Cooper, M, Ferrannini, E, Glasziou, P, Grobbee, D, Hamet, P, Harrap, S, Heller, S, Lisheng, L, Mancia, G, Marre, M, Mogensen, C, Neal, B, Yu Pan, C, Patel, A, Poulter, N, Rodgers, A, William, B, Woodward, M, Collins, R, Holman, R, Sleight, P, Adams, M, Branley, M, Fulcher, G, Jenkins, B, Louis, D, Lou, W, Lowe, H, McCormack, A, Mitchell, P, Ong, S, Pollock, C, Watson, J, Wong, T, Allen, S, Bompoint, S, Carreras, A, Chen, T, Flynn, S, Gibbo, S, Han, D, Hough, S, Jayne, K, Joshi, R, Kengne, AP, Linn, J, Monaghan, H, Ng, R, Perkovic, V, Regaglia, J, Schmidt, M, Xin, D, Yufang, B, Holloway, T, Gray, B, Milne, A, Adderkin, A, Guertin, MR, de Guise, D, Liyuan, M, Reid, J, Subramaniam, R, Wen, W & Williamson, K 2007, 'Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial', Health and Quality of Life Outcomes, vol. 5, 21. https://doi.org/10.1186/1477-7525-5-21
Glasziou, Paul ; Alexander, Jan ; Beller, Elaine ; Clarke, Philip ; Chalmers, John ; MacMahon, Stephen ; Cooper, Mark ; Ferrannini, Eleuterio ; Glasziou, Paul ; Grobbee, Diederick ; Hamet, Pavel ; Harrap, Stephen ; Heller, Simon ; Lisheng, Liu ; Mancia, Giuseppe ; Marre, Michel ; Mogensen, Carl ; Neal, Bruce ; Yu Pan, Chang ; Patel, Anushka ; Poulter, Neil ; Rodgers, Anthony ; William, Bryan ; Woodward, Mark ; Collins, Rory ; Holman, Rury ; Sleight, Peter ; Adams, Mark ; Branley, Michael ; Fulcher, Greg ; Jenkins, Bronwyn ; Louis, Damien ; Lou, Wei ; Lowe, Harry ; McCormack, Anne ; Mitchell, Paul ; Ong, Stephen ; Pollock, Carol ; Watson, John ; Wong, Tien ; Allen, Sarah ; Bompoint, Severine ; Carreras, Anna ; Chen, Tom ; Flynn, Samatha ; Gibbo, Sophie ; Han, Dorothy ; Hough, Sally ; Jayne, Kathy ; Joshi, Roshina ; Kengne, Andrew Pascal ; Linn, Jennifer ; Monaghan, Helen ; Ng, Robyn ; Perkovic, Vlado ; Regaglia, Joanne ; Schmidt, Manuela ; Xin, Du ; Yufang, Bi ; Holloway, Terry ; Gray, Barry ; Milne, Amanda ; Adderkin, Alison ; Guertin, Marie Renee ; de Guise, Danielle ; Liyuan, Ma ; Reid, Jane ; Subramaniam, Ravathi ; Wen, Wang ; Williamson, Karin. / Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. In: Health and Quality of Life Outcomes. 2007 ; Vol. 5.
@article{25c6b6d7b71d4600ab6efdd13ec9a453,
title = "Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial",
abstract = "Background: Diabetes has a high burden of illness both in life years lost and in disability through related co-morbidities. Accurate assessment of the non-mortality burden requires appropriate health-related quality of life and summary utility measures of which there are several contenders. The study aimed to measure the impact of diabetes on various health-related quality of life domains, and compare several summary utility measures. Methods: In the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) study, 978 Australian patients with Type 2 diabetes completed two health-related quality of life questionnaires at baseline: the EQ-5D and the SF-36v2, from which nine summary utility measures were calculated, and compared. The algorithms were grouped into four classes: (i) based on the EQ-5D; (ii) using fewer items than those in the SF-12 (iii) using the items in the SF-12; and (iv) using all items of the SF-36. Results: Overall health-related quality of life of the subjects was good (mean utility ranged from 0.68 (±0.08) to 0.85(±0.14) over the nine utility measures) and comparable to patients without diabetes. Summary indices were well correlated with each other (r = 0.76 to 0.99), and showed lower health-related quality of life in patients with major diabetes-related events such as stroke or myocardial infarction. Despite the smaller number of items used in the scoring of the EQ-5D, it generally performed at least as well as SF-36 based methods. However, all utility measures had some limitation such as limited range or ceiling effects. Conclusion: The summary utility measures showed good agreement, and showed good discrimination between major and minor health state changes. However, EQ-5D based measures performed as well and are generally simpler to use.",
author = "Paul Glasziou and Jan Alexander and Elaine Beller and Philip Clarke and John Chalmers and Stephen MacMahon and Mark Cooper and Eleuterio Ferrannini and Paul Glasziou and Diederick Grobbee and Pavel Hamet and Stephen Harrap and Simon Heller and Liu Lisheng and Giuseppe Mancia and Michel Marre and Carl Mogensen and Bruce Neal and {Yu Pan}, Chang and Anushka Patel and Neil Poulter and Anthony Rodgers and Bryan William and Mark Woodward and Rory Collins and Rury Holman and Peter Sleight and Mark Adams and Michael Branley and Greg Fulcher and Bronwyn Jenkins and Damien Louis and Wei Lou and Harry Lowe and Anne McCormack and Paul Mitchell and Stephen Ong and Carol Pollock and John Watson and Tien Wong and Sarah Allen and Severine Bompoint and Anna Carreras and Tom Chen and Samatha Flynn and Sophie Gibbo and Dorothy Han and Sally Hough and Kathy Jayne and Roshina Joshi and Kengne, {Andrew Pascal} and Jennifer Linn and Helen Monaghan and Robyn Ng and Vlado Perkovic and Joanne Regaglia and Manuela Schmidt and Du Xin and Bi Yufang and Terry Holloway and Barry Gray and Amanda Milne and Alison Adderkin and Guertin, {Marie Renee} and {de Guise}, Danielle and Ma Liyuan and Jane Reid and Ravathi Subramaniam and Wang Wen and Karin Williamson",
year = "2007",
month = "4",
day = "27",
doi = "10.1186/1477-7525-5-21",
language = "English",
volume = "5",
journal = "Health and Quality of Life Outcomes",
issn = "1477-7525",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial

AU - Glasziou, Paul

AU - Alexander, Jan

AU - Beller, Elaine

AU - Clarke, Philip

AU - Chalmers, John

AU - MacMahon, Stephen

AU - Cooper, Mark

AU - Ferrannini, Eleuterio

AU - Glasziou, Paul

AU - Grobbee, Diederick

AU - Hamet, Pavel

AU - Harrap, Stephen

AU - Heller, Simon

AU - Lisheng, Liu

AU - Mancia, Giuseppe

AU - Marre, Michel

AU - Mogensen, Carl

AU - Neal, Bruce

AU - Yu Pan, Chang

AU - Patel, Anushka

AU - Poulter, Neil

AU - Rodgers, Anthony

AU - William, Bryan

AU - Woodward, Mark

AU - Collins, Rory

AU - Holman, Rury

AU - Sleight, Peter

AU - Adams, Mark

AU - Branley, Michael

AU - Fulcher, Greg

AU - Jenkins, Bronwyn

AU - Louis, Damien

AU - Lou, Wei

AU - Lowe, Harry

AU - McCormack, Anne

AU - Mitchell, Paul

AU - Ong, Stephen

AU - Pollock, Carol

AU - Watson, John

AU - Wong, Tien

AU - Allen, Sarah

AU - Bompoint, Severine

AU - Carreras, Anna

AU - Chen, Tom

AU - Flynn, Samatha

AU - Gibbo, Sophie

AU - Han, Dorothy

AU - Hough, Sally

AU - Jayne, Kathy

AU - Joshi, Roshina

AU - Kengne, Andrew Pascal

AU - Linn, Jennifer

AU - Monaghan, Helen

AU - Ng, Robyn

AU - Perkovic, Vlado

AU - Regaglia, Joanne

AU - Schmidt, Manuela

AU - Xin, Du

AU - Yufang, Bi

AU - Holloway, Terry

AU - Gray, Barry

AU - Milne, Amanda

AU - Adderkin, Alison

AU - Guertin, Marie Renee

AU - de Guise, Danielle

AU - Liyuan, Ma

AU - Reid, Jane

AU - Subramaniam, Ravathi

AU - Wen, Wang

AU - Williamson, Karin

PY - 2007/4/27

Y1 - 2007/4/27

N2 - Background: Diabetes has a high burden of illness both in life years lost and in disability through related co-morbidities. Accurate assessment of the non-mortality burden requires appropriate health-related quality of life and summary utility measures of which there are several contenders. The study aimed to measure the impact of diabetes on various health-related quality of life domains, and compare several summary utility measures. Methods: In the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) study, 978 Australian patients with Type 2 diabetes completed two health-related quality of life questionnaires at baseline: the EQ-5D and the SF-36v2, from which nine summary utility measures were calculated, and compared. The algorithms were grouped into four classes: (i) based on the EQ-5D; (ii) using fewer items than those in the SF-12 (iii) using the items in the SF-12; and (iv) using all items of the SF-36. Results: Overall health-related quality of life of the subjects was good (mean utility ranged from 0.68 (±0.08) to 0.85(±0.14) over the nine utility measures) and comparable to patients without diabetes. Summary indices were well correlated with each other (r = 0.76 to 0.99), and showed lower health-related quality of life in patients with major diabetes-related events such as stroke or myocardial infarction. Despite the smaller number of items used in the scoring of the EQ-5D, it generally performed at least as well as SF-36 based methods. However, all utility measures had some limitation such as limited range or ceiling effects. Conclusion: The summary utility measures showed good agreement, and showed good discrimination between major and minor health state changes. However, EQ-5D based measures performed as well and are generally simpler to use.

AB - Background: Diabetes has a high burden of illness both in life years lost and in disability through related co-morbidities. Accurate assessment of the non-mortality burden requires appropriate health-related quality of life and summary utility measures of which there are several contenders. The study aimed to measure the impact of diabetes on various health-related quality of life domains, and compare several summary utility measures. Methods: In the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) study, 978 Australian patients with Type 2 diabetes completed two health-related quality of life questionnaires at baseline: the EQ-5D and the SF-36v2, from which nine summary utility measures were calculated, and compared. The algorithms were grouped into four classes: (i) based on the EQ-5D; (ii) using fewer items than those in the SF-12 (iii) using the items in the SF-12; and (iv) using all items of the SF-36. Results: Overall health-related quality of life of the subjects was good (mean utility ranged from 0.68 (±0.08) to 0.85(±0.14) over the nine utility measures) and comparable to patients without diabetes. Summary indices were well correlated with each other (r = 0.76 to 0.99), and showed lower health-related quality of life in patients with major diabetes-related events such as stroke or myocardial infarction. Despite the smaller number of items used in the scoring of the EQ-5D, it generally performed at least as well as SF-36 based methods. However, all utility measures had some limitation such as limited range or ceiling effects. Conclusion: The summary utility measures showed good agreement, and showed good discrimination between major and minor health state changes. However, EQ-5D based measures performed as well and are generally simpler to use.

UR - http://www.scopus.com/inward/record.url?scp=34249665476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249665476&partnerID=8YFLogxK

U2 - 10.1186/1477-7525-5-21

DO - 10.1186/1477-7525-5-21

M3 - Article

VL - 5

JO - Health and Quality of Life Outcomes

JF - Health and Quality of Life Outcomes

SN - 1477-7525

M1 - 21

ER -